Treatment Approach
Dr. Arman Danielyan specializes in the assessment and treatment of children, adolescents and young adults with various types of mental health problems. Dr. Danielyan is board certified by the American Board of Psychiatry & Neurology in Child & Adolescents, as well as in Adult Psychiatry. He offers a comprehensive personalized approach to your individual needs based on his deep knowledge of psychopharmacology (medication management) as well as psychotherapy of various psychiatric conditions.
Dr. Danielyan has significant clinical, academic and research backgrounds. Dr. Danielyan is a recipient of the Pilot Research Award by the American Academy of Child & Adolescent Psychiatry for his project, titled "Quality of Life in Adolescents with Bipolar Disorder with Comorbid Attention Deficit Hyperactivity Disorder: Role of Impaired Facial Emotion Processing and Social Cognition". Dr. Danielyan participated as a co-investigator in several clinical trials, including his work as an independent evaluator in the Treatment for Adolescents with Depression Study (TADS) – the largest NIMH funded study of depression in adolescents. He also co-authored book chapters in the Textbook of Pediatric Psychopharmacology and the Dulcan’s Textbook of Child and Adolescent Psychiatry – the books that Child & Adolescent Psychiatrists use to diagnose and treat psychiatric problems when they strike our children.
Dr. Danielyan has significant clinical, academic and research backgrounds. Dr. Danielyan is a recipient of the Pilot Research Award by the American Academy of Child & Adolescent Psychiatry for his project, titled "Quality of Life in Adolescents with Bipolar Disorder with Comorbid Attention Deficit Hyperactivity Disorder: Role of Impaired Facial Emotion Processing and Social Cognition". Dr. Danielyan participated as a co-investigator in several clinical trials, including his work as an independent evaluator in the Treatment for Adolescents with Depression Study (TADS) – the largest NIMH funded study of depression in adolescents. He also co-authored book chapters in the Textbook of Pediatric Psychopharmacology and the Dulcan’s Textbook of Child and Adolescent Psychiatry – the books that Child & Adolescent Psychiatrists use to diagnose and treat psychiatric problems when they strike our children.
|
|
Please call (925-385-8535) or email (info@moodychild.com) Dr. Danielyan if you have any symptoms of mental illness and want to be evaluated. Dr. Danielyan can also provide a second opinion and discuss alternative treatment options if you have already been diagnosed with mental illness and if your current treatment has not been effective. Dr. Danielyan can also help with referring you to another professional.
Major Pediatric Psychopharmacological Trials
Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS.
Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study.
The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation.
Characteristics of children with elevated symptoms of mania: the Longitudinal Assessment of Manic Symptoms (LAMS) study.
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
3-year follow-up of the NIMH MTA study.
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study.
Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I).
Predictors of parental accommodation in pediatric obsessive-compulsive disorder: findings from the Pediatric Obsessive-Compulsive Disorder Treatment Study (POTS) trial.
Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents.
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.
Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review.
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.
Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study.
The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation.
Characteristics of children with elevated symptoms of mania: the Longitudinal Assessment of Manic Symptoms (LAMS) study.
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
3-year follow-up of the NIMH MTA study.
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study.
Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I).
Predictors of parental accommodation in pediatric obsessive-compulsive disorder: findings from the Pediatric Obsessive-Compulsive Disorder Treatment Study (POTS) trial.
Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents.
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.
Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review.
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.